ImportantABT
Explain this story: Abbott Labs launches blood test to screen for colorectal cancer
Abbott Laboratories' Madison-based cancer diagnostics business has launched a new blood-based colorectal cancer screening test called SimpleScreen CRC. This new test aims to provide an alternative screening option for the estimated 60 million Americans who are overdue for colon screenings, especially for those who decline or do not complete traditional stool-based tests or colonoscopies. While traditional methods remain preferred by the American Cancer Society, this blood test offers a convenient option to detect colorectal cancer and precancerous growths at earlier, more treatable stages.
OtherWisconsin State JournalSector and industry: HealthcareMedical DevicesTell me moreShow less
We have not explained this story yet. The original headline, summary and link are below.
Abbott Laboratories' Madison-based cancer diagnostics business has launched a new blood-based colorectal cancer screening test called SimpleScreen CRC. This new test aims to provide an alternative screening option for the estimated 60 million Americans who are overdue for colon screenings, especially for those who decline or do not complete traditional stool-based tests or colonoscopies. While traditional methods remain preferred by the American Cancer Society, this blood test offers a convenient option to detect colorectal cancer and precancerous growths at earlier, more treatable stages.
Article tone: Positive This describes the words the journalist used. It is not a prediction, and not advice.
Published Sep 30, 2026, 16:00 ET · on this site +1h 16m